Literature DB >> 27755268

Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures.

Kimberly N Weaver1, Michael D Kappelman, Robert S Sandler, Christopher F Martin, Wenli Chen, Kristen Anton, Millie D Long.   

Abstract

BACKGROUND: As variation in care has previously been linked to quality, we aimed to describe variations in inflammatory bowel diseases care by gastroenterology (GI) practice setting.
METHODS: We performed a cross-sectional study within the Crohn's and Colitis Foundation of America Partners and used bivariate analyses to compare patient characteristics by GI practice setting (GI-academic [GIA], GI-private, or GI-other). Regression models were used to describe the effects of provider type on steroid use, disease activity, and the quality of life.
RESULTS: The study included 12,083 patients with inflammatory bowel diseases (7576 with Crohn's disease [CD] and 4507 with ulcerative colitis [UC]). Nearly 95% reported visiting a GI provider annually. Also, CD patients seen by GIA were younger, better educated, used less 5-aminosalicylate agents, and had higher biologic and immunomodulator use (P < 0.001 for all). On multivariate analysis of CD patients, GIA used less steroids when compared with GI-private (odds ratio, 0.84; 95% confidence interval, 0.67-1.06) or GI-other (odds ratio, 0.66; 95% confidence interval, 0.49-0.89). GIA patients were more likely to be in remission, have flu vaccine, and have better quality of life. UC patients seen by GIA were younger, had more hospitalizations, and previous surgery (P < 0.001 for all). No differences existed for steroid use, remission, flu vaccine, or quality of life for UC care on bivariate or multivariate analyses.
CONCLUSIONS: Significant variations in care patterns and quality measures exist for CD across GI provider types, without similar variation in UC care. Interventions to reduce variations in care could improve the quality of care in CD.

Entities:  

Mesh:

Year:  2016        PMID: 27755268      PMCID: PMC5278899          DOI: 10.1097/MIB.0000000000000933

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

1.  A comparison of acute coronary syndrome care at academic and nonacademic hospitals.

Authors:  Manesh R Patel; Anita Y Chen; Matthew T Roe; E Magnus Ohman; L Kristin Newby; Robert A Harrington; Sydney C Smith; W Brian Gibler; James E Calvin; Eric D Peterson
Journal:  Am J Med       Date:  2007-01       Impact factor: 4.965

Review 2.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

3.  Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?

Authors:  Emily O'Brien; Sumeet Subherwal; Matthew T Roe; DaJuanicia N Holmes; Laine Thomas; Karen P Alexander; Tracy Y Wang; Eric D Peterson
Journal:  Am Heart J       Date:  2014-02-22       Impact factor: 4.749

Review 4.  Implementing quality measures for inflammatory bowel disease.

Authors:  Shahzad Ahmed; Corey A Siegel; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2015-04

5.  Defining relapse of ulcerative colitis using a symptom-based activity index.

Authors:  S L Jowett; C J Seal; E Phillips; W Gregory; J R Barton; M R Welfare
Journal:  Scand J Gastroenterol       Date:  2003-02       Impact factor: 2.423

6.  Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis.

Authors:  P C Lunney; V C Kariyawasam; R R Wang; K L Middleton; T Huang; C P Selinger; J M Andrews; P H Katelaris; R W L Leong
Journal:  Aliment Pharmacol Ther       Date:  2015-05-12       Impact factor: 8.171

Review 7.  Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease.

Authors:  Corey A Siegel; John I Allen; Gil Y Melmed
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-05       Impact factor: 11.382

8.  The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.

Authors:  E J Irvine; Q Zhou; A K Thompson
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

Review 9.  ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network.

Authors:  Wallace Crandall; Michael D Kappelman; Richard B Colletti; Ian Leibowitz; John E Grunow; Sabina Ali; Howard I Baron; James H Berman; Brendan Boyle; Stanley Cohen; Fernando del Rosario; Lee A Denson; Lynn Duffy; Mark J Integlia; Sandra C Kim; David Milov; Ashish S Patel; Bess T Schoen; Dorota Walkiewicz; Peter Margolis
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

Review 10.  Approaches to improve quality of care in inflammatory bowel diseases.

Authors:  Rajesh Shah; Jason K Hou
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more
  9 in total

Review 1.  Quality Improvement Initiatives in Inflammatory Bowel Disease.

Authors:  Sameer K Berry; Corey A Siegel; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2017-08

2.  Medical Prophylaxis of Post-Surgical Crohn's Disease Recurrence: Towards Timely Anti-TNF Therapy.

Authors:  Adam C Fields; Nelya Melnitchouk
Journal:  Dig Dis Sci       Date:  2019-01       Impact factor: 3.199

3.  Sustained Improvement in Inflammatory Bowel Disease Quality Measures Using an Electronic Health Record Intervention.

Authors:  Andrew Bensinger; Farra Wilson; Patrick Green; Richard Bloomfeld; Ajay Dharod
Journal:  Appl Clin Inform       Date:  2019-12-04       Impact factor: 2.342

4.  A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease.

Authors:  Robert Battat; Jonathan S Galati; Dana Lukin; Fatiha Chabouni; Robbyn Sockolow; Jeff Carter; Kristina Fajardo; Stevie Yang; Jenna Reich; Vinita Jacobs; Meira Abramowitz; Anand Kumar; Paul Christos; Randy S Longman; Robert Burakoff; Laura Simone; Tamar Sapir; Carl V Crawford; Ellen J Scherl
Journal:  J Clin Gastroenterol       Date:  2022-03-01       Impact factor: 3.062

Review 5.  AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Authors:  Siddharth Singh; Deborah Proctor; Frank I Scott; Yngve Falck-Ytter; Joseph D Feuerstein
Journal:  Gastroenterology       Date:  2021-06       Impact factor: 33.883

6.  Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period.

Authors:  Reinier Cornelis Anthonius van Linschoten; Nikki van Leeuwen; Daan Nieboer; Erwin Birnie; Menne Scherpenzeel; Karen Evelyne Verweij; Vincent de Jonge; Jan Antonius Hazelzet; C Janneke van der Woude; Rachel Louise West; Desirée van Noord
Journal:  BMJ Open       Date:  2022-01-12       Impact factor: 2.692

7.  Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience.

Authors:  Manuel Barreiro-de Acosta; Ana Gutiérrez; Yamile Zabana; Belén Beltrán; Xavier Calvet; María Chaparro; Eugeni Domènech; Maria Esteve; Julian Panés; Javier P Gisbert; Pilar Nos
Journal:  United European Gastroenterol J       Date:  2021-06-05       Impact factor: 6.866

Review 8.  Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Authors:  Matthew Strohl; Lorant Gonczi; Zsuzsanna Kurt; Talat Bessissow; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2018-06-14       Impact factor: 5.742

9.  IBD2020 global forum: results of an international patient survey on quality of care.

Authors:  Peter Irving; Johan Burisch; Richard Driscoll; Mats Olsson; John R Fullarton; Barry S Rodgers-Gray; Simon Pl Travis
Journal:  Intest Res       Date:  2018-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.